Skip to content
Lomustine
Gleostine (lomustine) is a small molecule pharmaceutical. Lomustine was first approved as Gleostine on 1982-01-01. It is used to treat brain neoplasms, colonic neoplasms, hodgkin disease, kidney neoplasms, and lung neoplasms amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Gleostine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lomustine
Tradename
Company
Number
Date
Products
GLEOSTINECordenPharmaN-017588 RX1982-01-01
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
gleostineNew Drug Application2020-11-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
brain neoplasmsEFO_0003833D001932C71
colonic neoplasms—D003110C18
hodgkin disease—D006689C81
kidney neoplasmsEFO_0003865D007680C64
lung neoplasms—D008175C34.90
melanoma—D008545—
non-hodgkin lymphoma—D008228C85.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AD: Nitrosoureas, antineoplastic alkylating agents
— L01AD02: Lomustine
HCPCS
Code
Description
S0178
Lomustine, oral, 10 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLOMUSTINE
INNlomustine
Description
Lomustine is an N-nitrosourea that is urea in which one of the nitrogens is substituted by a 2-chloroethyl group and by a nitroso group, while the other nitrogen is substituted by a cyclohexyl group. An alkylating antineoplastic agent, it is used in the treatment of brain tumours, lung cancer, malignant melanoma and other solid tumours. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound.
Classification
Small molecule
Drug classantineoplastics (chloroethylamine derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=NN(CCCl)C(=O)NC1CCCCC1
Identifiers
PDB—
CAS-ID13010-47-4
RxCUI6466
ChEMBL IDCHEMBL514
ChEBI ID6520
PubChem CID3950
DrugBankDB01206
UNII ID7BRF0Z81KG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,474 documents
View more details
Safety
Black-box Warning
Black-box warning for: Gleostine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
152 adverse events reported
View more details